FDA cited Medinatura New Mexico for drug manufacturing rule violations, including weak component testing and cleaning.
What happened
FDA inspected the drug manufacturing facility in Albuquerque, New Mexico, from May 19 to May 23, 2025. Investigators found the company did not adequately test incoming components, including an active ingredient, relied on supplier certificates without validating them, lacked adequate cleaning validation for shared equipment, and had not validated production processes since 2007. FDA said these failures make the products adulterated, meaning they do not meet required drug quality standards.
What FDA found
The company did not test each incoming component lot for identity, purity, strength, and quality, and did not validate suppliers’ certificates of analysis.
21 CFR 211.84(d)(1) and 211.84(d)(2)Cleaning and maintenance procedures were inadequate; cleaning validation did not cover shared tablet equipment, hoses, or tanks, and equipment use and cleaning were not documented.
21 CFR 211.67(b)Production and process controls were not adequately validated for homeopathic drug products, including products with potentially hazardous components.
21 CFR 211.100(a)
What FDA wants
FDA tells Medinatura to correct the violations promptly and respond in writing within 15 working days with corrective actions, risk assessments, testing plans, and validation and cleaning program details. FDA also strongly recommends hiring a qualified CGMP consultant to audit the operation.
Who should pay attention
- brands that buy or distribute drugs from this firm
- other homeopathic drug manufacturers
- suppliers and contract testing labs for drug components
This is a summary. Read the original letter on fda.gov.